Table 2.
Study outcomes. Values are numbers (percentages) unless stated otherwise
| Outcome | All | Bacteraemia | |||||
|---|---|---|---|---|---|---|---|
| Trimethoprim-sulfamethoxazole | Vancomycin | Effect estimate (95% CI)* | Trimethoprim-sulfamethoxazole | Vancomycin | Effect estimate (95% CI)* | ||
| Treatment failure, day 7—ITT† | 51/135 (38) | 32/117 (27) | 1.38 (0.96 to 1.99) | 23/41 (56) | 20/50 (40) | 1.40 (0.91 to 2.16) | |
| Treatment failure, day 7—PP† | 37/110 (34) | 26/96 (27) | 1.24 (0.82 to 1.89) | 17/33 (52) | 15/42 (36) | 1.44 (0.85 to 2.44) | |
| All cause mortality, 30 days—ITT† | 19/135 (14) | 13/117 (11) | 1.27 (0.65 to 2.45) | 14/41 (34) | 9/50 (18) | 1.90 (0.92 to 3.93) | |
| All cause mortality, 30 days—PP† | 12/110 (11) | 10/96 (10) | 1.05 (0.47 to 2.32) | 9/33 (27) | 6/42 (14) | 1.91 (0.76 to 4.82) | |
| Treatment failure or modification‡ | 59/135 (42) | 45/117 (38) | 1.14 (0.84 to 1.53) | 24/41 (59) | 21/50 (42) | 1.39 (0.92 to 2.11) | |
| Bacteraemia duration >48 h | 11/135 (8) | 15/117 (13) | 0.64 (0.3 to 1.33) | 11/41 (27) | 15/50 (30) | 0.89 (0.46 to 1.73) | |
| Bacteriological failure, day 7 | 10/135 (7) | 4/117 (3) | 2.17 (0.7 to 6.73) | 6/41 (15) | 4/50 (8) | 1.83 (0.55 to 6.05) | |
| Hospital admission duration§ | 14 (11.6 to 16.4); (n=117) | 15 (14.5 to 15.5); (n=102) | −1 (−4.36 to 2.36) | 15 (7.1 to 22.9); (n=29) | 18 (8.6 to 27.4); (n=39) | −3 (−11.62 to 5.62) | |
| Fever duration§ | 1 (0.5 to 1.5); (n=132) | 1 (1 to 1); (n=114) | 0 (−0.49 to 0.49) | 2 (1.5 to 2.5); (n=40) | 2 (1 to 3); (n=48) | 0 (−0.7 to 0.7) | |
| Resistance development¶ | 5/135 (4) | 6/117 (5) | 0.72 (0.23 to 2.31) | — | — | — | |
*Risk ratios (95% CI) presented for categorical variables and median differences (95% CI) for continuous outcomes.
†ITT=intention to treat; PP=per protocol analysis; all other outcomes reported by intention to treat.
‡Failure at day 7 or deviation from assigned regimen in first seven days of treatment.
§Reported as median (95% CI) days. Hospital admission duration reported only for patients discharged alive.
¶One patient in each group developed TMP-SMZ resistant MRSA isolate; three TMP-SMZ and five vancomycin patients developed carbapenem resistant enterobacteriaceae colonization; no vancomycin intermediate or resistant S aureus or vancomycin resistant enterococcal isolates were found.